Ethinylestradiol/Chlormadinone Acetate: Benefits and Efficacy

The document from 19 years ago, written by Hans Peter Zahradnik, discussed the benefits of the oral contraceptive Ethinylestradiol/chlormadinone acetate (EE/CMA). The contraceptive was found to be very effective, with adjusted Pearl indices between 0.04 and 0.076. It had positive effects on menstrual cycle regulation and abnormal bleeding, and was well-tolerated, leading to excellent compliance in phase III and postmarketing surveillance studies. Notably, it significantly reduced dysmenorrhoea. The antiandrogenic effect of EE/CMA was confirmed, leading to clinical efficacy in mild-to-moderate androgen-induced skin and hair disorders, including androgenic alopecia. The rate of venous thromboembolism was very low. The study concluded that EE/CMA was an effective and safe method of contraception with clear additional benefits.